News coverage about BioCryst Pharmaceuticals (NASDAQ:BCRX) has trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioCryst Pharmaceuticals earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.3927237566476 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

BioCryst Pharmaceuticals (NASDAQ BCRX) traded up 0.18% during mid-day trading on Wednesday, reaching $5.62. 1,413,960 shares of the company traded hands. The stock has a 50-day moving average of $5.66 and a 200 day moving average of $6.45. BioCryst Pharmaceuticals has a 52-week low of $2.87 and a 52-week high of $9.25. The stock’s market capitalization is $451.96 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.01. The company had revenue of $9.40 million for the quarter, compared to the consensus estimate of $6.13 million. BioCryst Pharmaceuticals had a negative net margin of 150.24% and a negative return on equity of 323.86%. BioCryst Pharmaceuticals’s revenue was up 95.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.31) earnings per share. Equities research analysts expect that BioCryst Pharmaceuticals will post ($0.73) earnings per share for the current year.

Several research firms have recently commented on BCRX. Zacks Investment Research raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a research report on Tuesday, April 18th. Needham & Company LLC reiterated a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 12th. Finally, Noble Financial reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Sunday, May 28th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $8.29.

COPYRIGHT VIOLATION NOTICE: “BioCryst Pharmaceuticals (BCRX) Earns Daily Media Impact Score of 0.17” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/07/19/biocryst-pharmaceuticals-bcrx-earns-daily-media-impact-score-of-0-17.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Insider Buying and Selling by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.